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Sir,
The question asked by Spector and Ross is interesting because
birth weight is important in understanding parental smoking in
relation to hepatoblastoma. Two aspects may be worth clarifying:
(a) whether the association between parental smoking and
hepatoblastoma is due to the confounding effect of low birth
weight of the index child, and (b) whether the association between
parental smoking and hepatoblastoma is due to an indirect effect
of smoking through low birth weight rather than the direct effect of
smoking on fetal liver.
Our original analysis of parental prenatal smoking based on self-
reported data collected from parents of children with hepatoblas-
toma and parents of population controls, showed the following:
maternal smoking, OR¼2.68 (Po0.05); both parents smoking,
OR¼4.74 (Po0.01); maternal smoking in cases diagnosed at the
median age for hepatoblastoma or older, OR¼12.02 (Po0.01)
(Pang et al, 2003). We have now repeated the analyses adjusting for
low birth weight as well as parental age and deprivation. Low birth
weight was defined as less than 2000g (Moore and Persaud, 1993)
and treated as 0/1 binary variable. Results were obtained as
follows: maternal smoking OR¼2.50, both parents smoking
OR¼4.97, older children OR¼12.66, in all cases Po0.05. We
may conclude, therefore, that low birth weight does not explain the
observed association between parental smoking and hepatoblas-
toma.
We are not convinced that the association reflects an indirect
effect through low birth weight. Hepatoblastoma is an embryonal
tumour which most likely has a fetal origin and prenatal risk
factors probably play a more important role than postnatal risk
factors. The case for this may be made as follows: first, in some
children, hepatoblastoma is evident at birth or a few months after
birth (median age at diagnosis is about 1 year). Second,
histopathological examination shows striking similarities in size
and configuration between the developing fetal liver cells and the
fetal epithelial-type cells of hepatoblastoma. Third, the tumour’s
ability to synthesise alpha-fetoprotein (AFP) points to a fetal
origin. AFP, a major serum protein synthesised by fetal liver cells,
is also found in children with hepatoblastoma. Fourth, hepato-
blastoma, like Wilms’ tumour, is associated with Beckwith–
Wiedemann syndrome and hemihypertrophy, suggesting gesta-
tional oncogenic events (DeBaun and Tucker, 1998).
Furthermore, previous studies have shown that carcinogenic
metabolites of tobacco smoke can cross the placenta, the natural
barrier protecting the fetus from foreign substances, and the fetal
liver, as a detoxification organ, is immature and vulnerable to
carcinogens. A causal association with parental smoking is also
supported by the finding of G to T transversions in the TP53 gene
in hepatoblastoma (Olivier et al, 2002), a type of mutation that is
typical of smoking-induced carcinoma of the lung (Pfeifer et al,
2002).
In conclusion, our study suggests that parental smoking may
play a role in the development of hepatoblastoma. However, as we
stated, the finding may have arisen by chance since we carried out
many statistical comparisons. Further studies of parental smoking,
birth weight and other potential complications in relation to
hepatoblastoma would be helpful. As only about 15 cases of
hepatoblastoma occur each year in the UK and 100 cases a year in
the US, an international effort would be required.
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